• Humacyte highlighted research at the 2026 VASA dialysis access symposium showing its acellular tissue engineered vessel can self-repair following repeated dialysis needle use.
• Explanted grafts showed durable structure over years, with signs of tissue repopulation and remodeling at puncture sites versus standard synthetic grafts.
• The company expects top-line interim results from its V012 Phase 3 dialysis access study to be presented on June 11, 2026 at the SVS Vascular Annual Meeting.
• V012 targets female ESRD patients; positive data could support a supplemental Biologics License Application for a hemodialysis access indication in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260800PRIMZONEFULLFEED9726136) on May 26, 2026, and is solely responsible for the information contained therein.